290 related articles for article (PubMed ID: 36255682)
1. Gangliosides in Neurodegenerative Diseases.
Ledeen R; Chowdhury S
Adv Neurobiol; 2023; 29():391-418. PubMed ID: 36255682
[TBL] [Abstract][Full Text] [Related]
2. Systemic deficiency of GM1 ganglioside in Parkinson's disease tissues and its relation to the disease etiology.
Ledeen R; Chowdhury S; Lu ZH; Chakraborty M; Wu G
Glycoconj J; 2022 Feb; 39(1):75-82. PubMed ID: 34973149
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory role of GM1 and other gangliosides on microglia.
Galleguillos D; Wang Q; Steinberg N; Zaidi A; Shrivastava G; Dhami K; Daskhan GC; Schmidt EN; Dworsky-Fried Z; Giuliani F; Churchward M; Power C; Todd K; Taylor A; Macauley MS; Sipione S
J Neuroinflammation; 2022 Jan; 19(1):9. PubMed ID: 34991625
[TBL] [Abstract][Full Text] [Related]
4. A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease.
Schneider JS
Glycoconj J; 2022 Feb; 39(1):13-26. PubMed ID: 34037912
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to ganglioside GM1 in patients with Alzheimer's disease.
Chapman J; Sela BA; Wertman E; Michaelson DM
Neurosci Lett; 1988 Mar; 86(2):235-40. PubMed ID: 3368123
[TBL] [Abstract][Full Text] [Related]
6. The Key Role of GM1 Ganglioside in Parkinson's Disease.
Chowdhury S; Ledeen R
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204675
[TBL] [Abstract][Full Text] [Related]
7. Subnormal GM1 in PBMCs: Promise for Early Diagnosis of Parkinson's Disease?
Alselehdar SK; Chakraborty M; Chowdhury S; Alcalay RN; Surface M; Ledeen R
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768952
[TBL] [Abstract][Full Text] [Related]
8. The relationship between depletion of brain GM1 ganglioside and Parkinson's disease.
Sonnino S
FEBS Open Bio; 2023 Sep; 13(9):1548-1557. PubMed ID: 36638010
[TBL] [Abstract][Full Text] [Related]
9. Gangliosides in the Brain: Physiology, Pathophysiology and Therapeutic Applications.
Sipione S; Monyror J; Galleguillos D; Steinberg N; Kadam V
Front Neurosci; 2020; 14():572965. PubMed ID: 33117120
[TBL] [Abstract][Full Text] [Related]
10. GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson's Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson's Disease-Relevant Pathogenic Mechanisms.
Schneider JS
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298133
[TBL] [Abstract][Full Text] [Related]
11. Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans.
Wu G; Lu ZH; Kulkarni N; Ledeen RW
J Neurosci Res; 2012 Oct; 90(10):1997-2008. PubMed ID: 22714832
[TBL] [Abstract][Full Text] [Related]
12. GDNF signaling implemented by GM1 ganglioside; failure in Parkinson's disease and GM1-deficient murine model.
Hadaczek P; Wu G; Sharma N; Ciesielska A; Bankiewicz K; Davidow AL; Lu ZH; Forsayeth J; Ledeen RW
Exp Neurol; 2015 Jan; 263():177-89. PubMed ID: 25448159
[TBL] [Abstract][Full Text] [Related]
13. Gangliosides: Treatment Avenues in Neurodegenerative Disease.
Magistretti PJ; Geisler FH; Schneider JS; Li PA; Fiumelli H; Sipione S
Front Neurol; 2019; 10():859. PubMed ID: 31447771
[TBL] [Abstract][Full Text] [Related]
14. Intranasal infusion of GD3 and GM1 gangliosides downregulates alpha-synuclein and controls tyrosine hydroxylase gene in a PD model mouse.
Itokazu Y; Fuchigami T; Morgan JC; Yu RK
Mol Ther; 2021 Oct; 29(10):3059-3071. PubMed ID: 34111562
[TBL] [Abstract][Full Text] [Related]
15. Gangliosides--a new therapeutic agent against stroke and Alzheimer's disease.
Svennerholm L
Life Sci; 1994; 55(25-26):2125-34. PubMed ID: 7997071
[TBL] [Abstract][Full Text] [Related]
16. Synthetic GM1 improves motor and memory dysfunctions in mice with monoallelic or biallelic disruption of GM3 synthase.
Chowdhury S; Kumar R; Zepeda E; DeFrees S; Ledeen R
FEBS Open Bio; 2023 Sep; 13(9):1651-1657. PubMed ID: 37401916
[TBL] [Abstract][Full Text] [Related]
17. Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease.
Schneider JS; Seyfried TN; Choi HS; Kidd SK
PLoS One; 2015; 10(12):e0143351. PubMed ID: 26629687
[TBL] [Abstract][Full Text] [Related]
18. Gangliosides and glycolipids in neurodegenerative disorders.
Schneider JS
Adv Neurobiol; 2014; 9():449-61. PubMed ID: 25151391
[TBL] [Abstract][Full Text] [Related]
19. Gangliosides in nervous system development, regeneration, and pathologies.
Vasques JF; de Jesus Gonçalves RG; da Silva-Junior AJ; Martins RS; Gubert F; Mendez-Otero R
Neural Regen Res; 2023 Jan; 18(1):81-86. PubMed ID: 35799513
[TBL] [Abstract][Full Text] [Related]
20. Deciphering the glycolipid code of Alzheimer's and Parkinson's amyloid proteins allowed the creation of a universal ganglioside-binding peptide.
Yahi N; Fantini J
PLoS One; 2014; 9(8):e104751. PubMed ID: 25140899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
